MWPCG
JAZZ icon

Measured Wealth Private Client Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Measured Wealth Private Client Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$700K Sell
3,701
-242
-6% -$42.3K 0.19% 81
2025
Q4 		$670K Sell
3,943
-705
-15% -$108K 0.18% 77
2025
Q3 		$613K Sell
4,648
-207
-4% -$24.8K 0.17% 84
2025
Q2 		$515K Buy
4,855
+1,554
+47% +$169K 0.15% 97
2025
Q1 		$410K Buy
+3,301
New +$431K 0.13% 109

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Measured Wealth Private Client Group's JAZZ Position: Q1 2026 in Review

Measured Wealth Private Client Group reduced its Jazz Pharmaceuticals (JAZZ) stake by 6.1% in Q1 2026, selling an estimated $42.3K and leaving 3,701 shares worth $700K. The position accounts for 0.19% of the portfolio, ranked #81.

Measured Wealth Private Client Group first reported a position in JAZZ in Q1 2025 and has held it in 5 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Measured Wealth Private Client Group held 3,701 shares of Jazz Pharmaceuticals worth $700K as of Q1 2026.
  • Measured Wealth Private Client Group sold 242 Jazz Pharmaceuticals shares in Q1 2026, an estimated $42.3K.
  • Jazz Pharmaceuticals made up 0.19% of Measured Wealth Private Client Group's portfolio in Q1 2026, its #81 holding.
  • Measured Wealth Private Client Group first reported a position in Jazz Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Measured Wealth Private Client Group's 13F filing for Q1 2026, filed 13 May 2026.